# Myriad Genetics share price today (Myriad Genetics, Inc., MYGN)

> Myriad Genetics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. MYGN · Healthcare · Diagnostics & Research · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/mygn

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $6.04 (−24.9% in a year)
- Revenue (Jun 2026): $191 M (−10.5% on a year ago)
- Profit (Jun 2026): −$43.2 M
- Operating margin: −20.4% (−14.5 points on a year ago)
- ROE: −99%, FY25
- ROIC: −22.0%, against a 11.4% cost of capital: −33.4 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Myriad Genetics share price today? Myriad Genetics, Inc.'s share price was $6.04 at the close on 3 November 2026. It has been stalling near its high for 3 weeks. That is 31.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $8, and at that close it sat 67% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 3 weeks in a row. Over the last 10 years the share price moved −81% while the S&P 500 moved +255%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Myriad Genetics pay? Myriad Genetics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Myriad Genetics on? Myriad Genetics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Myriad Genetics profitable? Myriad Genetics, Inc. posted a net loss of $43.2 M in the Jun 2026 quarter. The full FY25 year was a loss of $366 M. That loss is 22.7% of the quarter's revenue. The same quarter a year earlier lost $331 M. 12 of the last 12 reported quarters were loss-making. ## How much revenue does Myriad Genetics make, and is it growing? Myriad Genetics, Inc. reported $191 M of revenue in the Jun 2026 quarter, −10.5% on the same quarter a year earlier. Over 4 years it has grown 4.5% a year on average. The last full year, FY25, came in at $825 M. The last four reported quarters add to $807 M. FY25 revenue was $825 M, −1.6% on the year before. Recent pace: the last four quarters grew −3.0% on average, against 4.5% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −3.2%, against +0.3% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does Myriad Genetics keep? Myriad Genetics, Inc.'s operating margin was −20.4% in the Jun 2026 quarter, 14.5 percentage points lower than the same quarter a year ago. Across 5 years it has been between −19.2% and −8.2%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −14.5 percentage points on the year while gross margin changed −4.6 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Myriad Genetics' profit turning into cash? Myriad Genetics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $1.8 M of operating cash against −$366 M of profit. After $15.6 M of spending on assets, free cash was −$13.8 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Myriad Genetics' cash go? Myriad Genetics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $97.8 M on assets over the last 3 years. Averaged over those years that is 4.0% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $97.8 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Myriad Genetics' P/E ratio, and how does it compare with its own history? Myriad Genetics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Myriad Genetics, Inc. at 0.7× its FY25 revenue of $825 M. The P/E comes back here once profit turns positive. ## Is the Myriad Genetics business getting better or worse? Myriad Genetics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Myriad Genetics earn on its capital? Myriad Genetics, Inc. earned a ROE of −99% in FY25. Its return on capital used (ROIC) is 33.4 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −44.4% net margin and 1.17× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −44.4% net margin × 1.17× asset turnover × 1.92× leverage (assets divided by equity) ≈ −99.7% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: −22.0% − 11.4% = −33.4 percentage points. The 11.4% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −22.0% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −11.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Myriad Genetics have too much debt? Myriad Genetics, Inc. has total debt of $211 M against shareholder equity of $304 M as of Jun 2026, so its debt is 0.69× its equity. Year by year, that ratio went from 0.10 in FY21 to 0.57 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Myriad Genetics shareholding pattern? 11.7% of Myriad Genetics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 4.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Myriad Genetics from balance-sheet trouble? For Myriad Genetics, Inc., the Z-score is −0.58. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −0.58 is inside the danger zone, so the balance sheet is a real risk. ## How does Myriad Genetics rank in its industry? There is no score against its industry: Myriad Genetics, Inc. is not among the largest members shown in this industry comparison for Diagnostics & Research. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Myriad Genetics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Myriad Genetics in size? Myriad Genetics is the 31st largest of 34 Diagnostics & Research companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Personalis, Inc., OPKO Health, Inc. and Castle Biosciences, Inc. Just below it: Fulgent Genetics, Inc., Biodesix, Inc. and Exagen Inc. ### Diagnostics & Research companies close in size

1. [Personalis, Inc.](https://www.sectoralpha.in/us/stocks/psnl) $1.7 billion
2. [OPKO Health, Inc.](https://www.sectoralpha.in/us/stocks/opk) $1.3 billion
3. [Castle Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/cstl) $1.1 billion
4. Myriad Genetics, Inc. $578 million
5. [Fulgent Genetics, Inc.](https://www.sectoralpha.in/us/stocks/flgt) $533 million
6. [Biodesix, Inc.](https://www.sectoralpha.in/us/stocks/bdsx) $222 million
7. [Exagen Inc.](https://www.sectoralpha.in/us/stocks/xgn) $202 million

[All 34 Diagnostics & Research companies, largest first](https://www.sectoralpha.in/us/sectors/diagnostics-research#all-companies)

### Companies close in size in other industries

1. [Energy Vault Holdings, Inc.](https://www.sectoralpha.in/us/stocks/nrgv) $562 million · Utilities - Renewable
2. [DBV Technologies S.A.](https://www.sectoralpha.in/us/stocks/dbvt) $562 million · Biotechnology
3. Myriad Genetics, Inc. $560 million
4. [Evotec SE](https://www.sectoralpha.in/us/stocks/evo) $559 million · Drug Manufacturers - Specialty & Generic
5. [GeoPark Limited](https://www.sectoralpha.in/us/stocks/gprk) $559 million · Oil & Gas Exploration & Production

## What else do people ask about Myriad Genetics? ### What were Myriad Genetics's latest quarterly results? Myriad Genetics, Inc. reported revenue of $191 M and a net loss of $43.2 M for the Jun 2026 quarter. Earnings per share were −$0.46. The operating margin was −20.4%, 14.5 percentage points lower than a year earlier (as of 3 November 2026). ### What is Myriad Genetics's market cap? Myriad Genetics, Inc.'s market capitalisation is $578 M at a stock price of $6.04. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Myriad Genetics performing? Myriad Genetics, Inc.'s share price has been stalling near its high for 3 weeks. Over the past 13 weeks it has done better than the S&P 500, for 3 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Myriad Genetics's stock price go up? This page does not forecast Myriad Genetics, Inc.'s stock price. What it shows instead: the stock price is $6.04, and it has been stalling near its high for 3 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Myriad Genetics in its business cycle? Myriad Genetics, Inc.'s FY25 operating margin was −8.2%, against a 5-year range of −19.2% to −8.2%: the middle of its own range, neither a peak nor a low. The latest quarter was −20.4%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Myriad Genetics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Myriad Genetics a stock worth studying right now? What the numbers show: Myriad Genetics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.